Molecular Profiles Strengthens US Presence to Drive Growth
Molecular Profiles Ltd, a subsidiary of Columbia Laboratories, Inc., is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales.
The development and manufacturing services provider, which has a well-established track record for meeting objectives while tightening development timelines for its clients, has hired Charles D. Maher to expand its client base in the US.
Mr Maher brings extensive senior commercial experience in the global contract services market to this newly-created position. He will focus on presenting the benefits of Molecular Profiles’ unique expertise in combining enabling technologies with advanced characterisation, formulation development and manufacturing.
The organisation recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology to further enhance its expertise in the processing of difficult-to-progress molecules. Leveraging the location of its Boston-based parent company, Molecular Profiles expects its advanced knowledge in characterisation and dealing with complex molecules will resonate with many US firms.
Dr Nikin Patel, chief executive officer at Molecular Profiles, said: “Over the years, we have built a solid reputation in Europe for applying a science driven approach to our clients’ development challenges in a cost-effective manner that delivers value by accelerating development. We are now striding toward executing our strategy to replicate this success in the US.
“I am delighted to welcome Charles to the company. His extensive knowledge of the market, experience and strong industry contacts should benefit our efforts to capitalize on our state-of-the-art facility, manufacturing capabilities and growing suite of enabling technologies among pharmaceutical and biotech companies.”
“Building our business in the US brings us closer to our current US-based customers and improves our service to them, while supporting our on-going initiative to expand our pharmaceutical development services client base.”
Mr Maher has held senior roles in the sector and most recently was Vice President of Business Global Development/ USA and Europe for an international pharmaceutical R&D services company.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance